** Shares of biopharma firm Ocular Therapeutix OCUL.O fall 13% to $6.21
** Company posts quarterly revenue of $17.08 million compared with analysts' estimates of $17.20 million, according data compiled by LSEG
** Reports Q4 loss of 29 cents per share compared to analysts' estimates of 25 cents
** Company delays data from late-stage study testing its drug, axpaxli, to treat wet age-related macular degeneration (wet AMD) to Q1 2026 from Q4 2025 as the FDA allows changes to study design through Special Protocol Agreement $(SPA.UK)$
** Wet AMD is a condition where abnormal blood vessels grow under the retina, leading to vision loss
** OCUL has fallen 28.2% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。